1. Orbomed
EARLY DIAGNOSIS – TIMELY CURE

2. Orbomed team
Vitaly Vishnepolsky, MBA CEO Dr. Vadim Sigalov, MD
Chief Business consultant Chief Medical consultant
Ksenia Chagan, MBA Igor Shcherback, PhD
Biotech advisor Physics advisor

3. Hysteroscopy: background
• Gold standard for detection
of intrauterine pathology
• Safe and simple procedure
for outpatient clinics

4. Hysteroscopy: background (cont.)
• From patients’ side pain continues to
represent the main limiting factor to a
large-scale use of outpatient hysteroscopy

5. Office Based Hysteroscopy
(OBH) facts
• Only 15% of gynecologists in the United States
routinely perform office hysteroscopy to evaluate
intrauterine pathology.
Reimbursement
Equipment

6. The OBH need
• Broadening of applications’ list
• Cost reduction
• Becoming the gold standard
for specific operations
• Updating of reimbursement
policies.

7. Orbomed:
Office Based Hysteroscopy product line
• Three dimensional scissors
• No need for laparoscop reposition
• Easier lesion capture in moving media (saline flow)
• Ready-for-sending tissue sample post-operationally

8. What is the difference in
ORBOMED concept?
VIDEO>>

9. Advantages of Orbomed
• Improved patient’s comfort
• Eliminated need for general anesthesia
• Shorten interventional procedure
• Reduced overall cost

10. Target Customers
Private/public gynecological clinics

11. Applications
• Polypectomy – 6M of annual visits
• Adhesiolysis – 1M of Asherman Syndrome
• Biopsy under direct visualization – approx. 50K
of new endometrial cancer/year

12. Market potential
• Global Uro-Gynecological
Surgical Devices Market to
Reach US$1.98 Billion by
2015
• Global Biopsy devices
Market is expected to
reach $1.4 Billion by 2018,
CAGR 5% from 2011.

13. Orbomed R&D plan
• Within 24 months we plan to achieve fully
working prototype ready for clinical trials
• Planned budget $750K

14. ‫‪Budget‬‬
‫שיווק‬
‫שונות‬ ‫%9‬
‫ציוד‬ ‫%31‬
‫שכר‬
‫%3‬
‫%24‬
‫קבלני משנה‬
‫%92‬
‫חומרים וציוד‬
‫מתכלה‬
‫%4‬

15. Thank you